- Exchange: Copenhagen
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Large Pharmaceuticals
Novo Nordisk A/S
+ Add to WatchlistNOVOB:DC
887.500 DKK 18.000 1.99%
Share
As of 11:05:37 ET on 06/19/2013.
More on NOVOB
News for Novo Nordisk A/S (NOVOB)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Lundbeck Fined $125.6 Million by EU Drug Delay Probe
- Marathon Patent, Novo Nordisk: Intellectual Property
- Novo Drops as New Lilly Drug Threatens Victoza: Copenhagen Mover
- Merck Joins Novo to Reassure FDA of Diabetes Drug Safety
- Banks Fighting Capital Rules in Denmark Get Slammed by Rohde
- Danish Central Bank Cuts Growth Forecast as Europe Hurts Economy
- European Stocks Fall for Second Day Amid Stimulus Debate
- ‘Love Hormone’ Promises Safer Births After Pfizer Flop
- Zealand Gains as Sanofi Will Speed Up Lyxumia: Copenhagen Mover
- Novo Nordisk Insulin Revenue Drives 1Q Profits
- Novo Nordisk's Main Europe Problem Is Reimbursement
- Novo Nordisk First-Quarter Profit Climbs on Insulins, Victoza
- Daily Soft Drinks Raise Diabetes Risk by 22%, Study Shows
- Pfizer CEO Was Highest Paid Among Pharma Companies Last Year
- Novo Lures Sanofi Pitchman as Diabetes Battle Heats Up
- Novo Nordisk A/S: Federal Circuit Court rules on patent litigation involving Prandin(R) (repaglinide) Published Jun 18, 2013
- Novo Nordisk A/S : Novo Nordisk A/S: Federal Circuit Court rules on patent litigation involving Prandin® (repaglinide) Published Jun 18, 2013
- Novo Nordisk A/S - Share repurchase programme Published Jun 17, 2013
- Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme Published Jun 17, 2013
- Victoza® (liraglutide [rDNA origin] injection) safety profile further supported at scientific workshop on pancreatitis, Published Jun 13, 2013
- Resolutions of the Annual General Meeting of Evotec AG Published Jun 12, 2013
- ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials Published Jun 10, 2013
- Novo Nordisk A/S - Share repurchase programme Published Jun 10, 2013
- New Studies, Regulatory Submissions, and Leadership Changes - Research Report on St. Jude Medical, Teva Pharmaceutical Published Jun 10, 2013
- Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme Published Jun 10, 2013
- Novo Nordisk A/S :Share repurchase programme Published Jun 03, 2013
- Novo Nordisk A/S : Novo Nordisk A/S :Share repurchase programme Published Jun 03, 2013
- Novo Nordisk A/S: Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes Published May 31, 2013
- Novo Nordisk A/S : Novo Nordisk A/S: Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type Published May 31, 2013
- INNATE PHARMA : INNATE PHARMA : number of shares outstanding as well as its voting rights as at May 17, 2013 Published May 29, 2013
- Pfizer Share Swap for Animal Health Stake Hits Top Limit Updated 3 hours ago
- U.S. Company Credit Swaps Rise Most in Year After Fed Statement
- Cancer-Causing Sex Virus Cut in Teen Girls by Vaccines
- Nektar Therapeutics Gains on Trial of New Painkiller
- Valeant Plans $7.3 Billion in Loans, Bonds for Bausch Purchase
- Valeant Seeks $4.05 Billion in Loans for Bausch & Lomb Purchase
- To Taper or Not?: In The Loop (06/18)
- Lundbeck Fined $125.6 Million by EU Drug Delay Probe
- Marathon Patent, Novo Nordisk: Intellectual Property
- Swiss Stocks Decline Before Fed Statement on Stimulus
- Almirall CEO on International Expansion, Porfolio
- Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel
- Medtronic’s Infuse No Better Than Bone Graft With Risk
- FDA Investigating Lilly’s Zyprexa Injection After Two Die
- Global Power Players: In The Loop (06/14)
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page